Verdict: Side-by-side breakdown using the Bull Rankings model. MEDP scored 76.6, RDNT scored 38.0 — MEDP leads.
Compare another set
MEDP
Medpace Holdings, Inc.
Diagnostics & Research · Quality-Growth
76.6
$612.05 · $17.1B
fundamentals as of
Score gap
38.6
MEDP leads
RDNT
RadNet, Inc.
Diagnostics & Research · Quality-Growth
38
$70.91 · $5.6B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
Fastest growthMEDP+24.7%
Strongest balance sheetMEDP0.33
Highest qualityMEDP87 / 100
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
MEDP
stronger →← stronger
RDNT
87
Qualityreturns · margins · balance sheet
35
88
Growthrevenue & earnings expansion
86
58
Valuevaluation vs sector peers
18
MEDP is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
MEDP
RDNT
$707mC+
FCF
$236mC
+24.7%A-
Rev
+18.9%B+
0.33B
D/E
1.57C
35.9xC+
P/E
—
2.87C
PEG
0.96B+
—
P/S
2.5xB+
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
MEDP
RDNT
26% above
Price vs fair valuelower is cheaper
53% above
~20%/yr
Growth the price impliesyr-1 FCF growth, fading to 4% · lower = less priced in
~23%/yr
-37%
1-yr DCF upside
-46%
-21%
5-yr DCF upside
-35%
+10%
10-yr DCF upside
-16%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
MEDP
Why this score
Durable high returns
RDNT
Why this score
Diluting shareholders
The companies
MEDPMedpace Holdings, Inc.
Diagnostics & Research · $612.05 · beta 1.18
Why now
Diagnostics & Research · market cap $17.1b. 10% off the 52-week high of $677.90. Revenue growing +25%, comfortably above the S&P median. 13 sell-side analysts rate this a Hold with a mean 1-yr target of $595.92 (implying -3% upside).
Moat
Net margin 18% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. FCF converts 144% of net income, helped by cash released from working capital ($120m) that doesn't repeat every year.
Risk
Trailing P/E 36x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
RDNTRadNet, Inc.
Diagnostics & Research · $70.91 · beta 1.41
Why now
Diagnostics & Research · market cap $5.6b. 17% off the 52-week high of $85.84. Revenue growing +19%, comfortably above the S&P median. PEG 0.96 — paying under fair value for the growth rate. 8 sell-side analysts publish a mean 1-yr target of $94.63 (implying +33% upside).
Moat
Turnaround / out-of-favor name — GAAP-unprofitable for now, so the durability case is forward-looking: it rests on a recovery (margin normalization, a cyclical upturn or restructuring) or an un-monetized asset (IP / network effects / first-mover position) rather than on current reported results.
Risk
Currently unprofitable (margin -0.9%) — path to GAAP profitability is the core thesis risk. Beta 1.41 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where MEDP and RDNT diverge
On the headline score the gap is 38.6 points in favor of MEDP. The widest single difference is Quality, where MEDP leads by 52.5 points.
QualityMEDP 87.4 · RDNT 34.9MEDP +52.5
ValueMEDP 58.4 · RDNT 18.2MEDP +40.2
GrowthMEDP 88.3 · RDNT 86.5level
Pillars run 0–100. Value is judged against each company's own sector, so a Value score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.
Common questions
Is MEDP or RDNT the better stock?
MEDP scores higher: MEDP 76.6, RDNT 38.0 out of 100 on the Bull Rankings quality-growth score, which blends business quality, growth and valuation into one number. A higher score means a stronger business at a more reasonable price — it is not a price target or a recommendation.
Where do MEDP and RDNT differ most?
The widest gap is quality, where MEDP leads by 53 points on the 0–100 pillar scale. MEDP also leads value, while growth is effectively level between them.
How are MEDP and RDNT scored?
Each carries the same 0–100 quality-growth score used everywhere on the site, built from three pillars — quality (profitability and returns on capital), growth (revenue and earnings), and value (what you pay for them) — combined as a geometric mean, so a weak pillar cannot be papered over by a strong one.
How current is this comparison?
The whole universe is re-scored every trading day after the US market close, so the scores and fundamentals here reflect the latest published edition.